NCT04768491 2021-02-24
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Peking Union Medical College
Unknown
Clinical Trials
3 trialsNCT04675008 2021-01-05
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
Phase 2 Unknown
NCT04339829 2020-04-09
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Guangdong Association of Clinical Trials
Phase 2 Unknown